Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2017-07-03,10% Owner,HBM Healthcare Investments (Ca ,卖出,11352普通股, $10.95
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2017-06-30,10% Owner,HBM Healthcare Investments (Ca ,卖出,1775普通股, $10.94
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ F-6 POS - Post-effective amendments for immediately effective filing Filed: 2017-06-30 AccNo: 0001201935-17-000002 Size: 48 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2017-06-29,10% Owner,HBM Healthcare Investments (Ca ,卖出,1603普通股, $10.72
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2017-06-28,10% Owner,HBM Healthcare Investments (Ca ,卖出,4789普通股, $11.10
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2017-06-27,10% Owner,HBM Healthcare Investments (Ca ,卖出,2166普通股, $10.83
$Nabriva Therapeutics AG - American Depositary Shares(NBRV)$ SC 14D9/A [Amend] - Solicitation, recommendation statements Filed: 2017-06-27 AccNo: 0001104659-17-041854 Size: 56 KB 网页链接
$Nabriva Therapeutics AG - American Depositary Shares(NBRV)$ SC TO-T/A [Amend] - Tender offer statement by Third Party Filed: 2017-06-27 AccNo: 0001104659-17-041853 Size: 55 KB 网页链接
$Nabriva Therapeutics AG - American Depositary Shares(NBRV)$ 内部交易: 2017-06-19,Director,Talbot George Harrison ,卖出,46普通股, $91.00
$Nabriva Therapeutics AG - American Depositary Shares(NBRV)$ 内部交易: 2017-06-16,Director,Talbot George Harrison ,卖出,24普通股, $93.50